Mark J. Rosenblum is CFO & Exec VP Finance at Salarius Pharmaceuticals, Inc. (SLRX). They have made 7 open-market trades across 2 companies since 2013, most recently 2026-08-31.
CIK 0001329154
7 open-market purchases totalling $110K since 2013, never a sale. Across 6 scored buys the stock is down 12.8% at ninety days, and 8.6 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ADXS | 113,822 | $27K |
| SLRX | 20,177 | $17K |
| DCOY | 11,363 | — |
| HMBT.OB | 293,234 | — |
| Total | $44K |
Shares reported on the most recent Form 4, priced at the 2026-09-02 close. 2 holdings could not be priced and are excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 14% | 50% |
| Avg Move | -7.4% | -16.4% | -12.8% |
| Alpha | -5.0% | -7.6% | -8.6% |
| Scored | 7 | 7 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SLRX | BUY | 2025-11-20 | 2025-11-20 | $0.80 | $16K | +10.7% | -14.1% | N/A |
| SLRX | BUY | 2022-05-31 | 2022-05-31 | $0.18 | $5K | -2.0% | +0.0% | +2.5% |
| SLRX | BUY | 2022-03-03 | 2022-03-09 | $0.39 | $30K | -11.5% | -14.6% | -57.1% |
| SLRX | BUY | 2020-08-17 | 2020-08-18 | $1.00 | $5K | -10.7% | -22.9% | -33.7% |
| SLRX | BUY | 2020-02-19 | 2020-02-20 | $0.95 | $2K | -17.1% | -41.4% | +18.1% |
| SLRX | BUY | 2020-02-13 | 2020-02-13 | $0.86 | $4K | -3.5% | -22.2% | -7.4% |
| ADXS | BUY | 2013-10-24 | 2013-10-28 | $4.00 | $48K | -17.7% | +0.5% | +0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.